Fasting C-peptide at type 2 diabetes diagnosis is an independent risk factor for total and cancer mortality.
Julia OttenBjörn TavelinStefan SöderbergOlaf RolandssonPublished in: Diabetes/metabolism research and reviews (2021)
Fasting C-peptide at type 2 diabetes diagnosis is an independent risk factor for total and cancer-related mortality. Thus, treatment of type 2 diabetes should focus not only on normalising blood glucose levels but also on mitigating insulin resistance.
Keyphrases
- blood glucose
- glycemic control
- type diabetes
- insulin resistance
- cardiovascular events
- adipose tissue
- papillary thyroid
- weight loss
- polycystic ovary syndrome
- skeletal muscle
- blood pressure
- metabolic syndrome
- high fat diet
- cardiovascular disease
- high fat diet induced
- squamous cell
- squamous cell carcinoma
- combination therapy
- lymph node metastasis
- replacement therapy